Medicxi Ventures Management’s Aura Biosciences AURA Stock Holding History

Medicxi Ventures Management’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.6M	Hold	3,039,892	–	–	12.16%	3
2026 Q1	$20.3M	Hold	3,039,892	–	–	2.07%	4
2025 Q4	$16.6M	Hold	3,039,892	–	–	1.98%	5
2025 Q3	$18.8M	Hold	3,039,892	–	–	2.52%	5
2025 Q2	$19M	Hold	3,039,892	–	–	4.45%	5
2025 Q1	$17.8M	Hold	3,039,892	–	–	4.07%	5
2024 Q4	$25M	Hold	3,039,892	–	–	4.72%	5
2024 Q3	$27.1M	Hold	3,039,892	–	–	5.12%	4
2024 Q2	$23M	Hold	3,039,892	–	–	6.85%	4
2024 Q1	$23.9M	Hold	3,039,892	–	–	5.31%	5
2023 Q4	$26.9M	Hold	3,039,892	–	–	9.09%	5
2023 Q3	$27.3M	Hold	3,039,892	–	–	8.71%	5
2023 Q2	$37.5M	Hold	3,039,892	–	–	10.52%	5
2023 Q1	$28.2M	Hold	3,039,892	–	–	12.09%	4
2022 Q4	$31.9M	Hold	3,039,892	–	–	13.41%	3
2022 Q3	$55.1M	Hold	3,039,892	–	–	22.93%	2
2022 Q2	$43.1M	Hold	3,039,892	–	–	17.89%	2
2022 Q1	$66.9M	Hold	3,039,892	–	–	18.12%	2
2021 Q4	$51.6M	Buy	+3,039,892	New	+$54.3M	12.92%	2

Other funds holding AURA

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Medicxi Ventures Management's AURA Position: Q2 2026 in Review

Medicxi Ventures Management held its Aura Biosciences (AURA) position steady in Q2 2026 at 3,039,892 shares worth $21.6M. The position accounts for 12.16% of the portfolio, ranked #3.

Medicxi Ventures Management first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. The position peaked at $66.9M in Q1 2022. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

Medicxi Ventures Management held 3,039,892 shares of Aura Biosciences worth $21.6M as of Q2 2026.
Medicxi Ventures Management left its Aura Biosciences share count unchanged in Q2 2026.
Aura Biosciences made up 12.16% of Medicxi Ventures Management's portfolio in Q2 2026, its #3 holding.
Medicxi Ventures Management first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
Medicxi Ventures Management's Aura Biosciences position peaked at $66.9M in Q1 2022.
147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Medicxi Ventures Management's 13F filing for Q2 2026, filed 4 Aug 2026.